X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, EffRx will grant Radius an exclusive, royalty bearing license to Binosto (alendronate sodium), an effervescent tablet for oral solution indicated for osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis, in the US.
Lead Product(s): Alendronate Sodium
Therapeutic Area: Musculoskeletal Product Name: Binosto
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: EffRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 19, 2023
Details:
Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or metastatic breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: Orserdu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: DRI Healthcare
Deal Size: $140.0 million Upfront Cash: $130.0 million
Deal Type: Agreement August 14, 2023
Details:
Theramex will commercialise and distribute Eladynos (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures on an exclusive basis in the European Economic Area, UK , Australia and Brazil.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Eladynos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Theramex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2023
Details:
Elacestrant (RAD1901), if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Tymlos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 15, 2022
Details:
The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Tymlos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $890.0 million Upfront Cash: $547.0 million
Deal Type: Acquisition August 15, 2022
Details:
Investigational drug RAD011 is a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes.
Lead Product(s): Cannabidiol
Therapeutic Area: Genetic Disease Product Name: RAD011
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
The acquisition of Radius by Gurnet Point and Patient Square provides our shareholders with attractive, immediate value at a compelling premium, in addition to the potential future upside of TYMLOS (abaloparatide) through the CVR.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: Tymlos
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Gurnet Point Capital
Deal Size: $890.0 million Upfront Cash: $547.0 million
Deal Type: Acquisition June 23, 2022
Details:
RAD1901 (elacestrant) is the first and currently only investigational oral SERD to show positive topline results in a pivotal trial for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women, and men.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Elacestrant (RAD1901), is an investigational selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer.
Lead Product(s): Elacestrant
Therapeutic Area: Oncology Product Name: RAD1901
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
